Browse the evidence

Testosterone replacement therapy in hypogonadal men produces heterogeneous time-courses for physiological effects, with sexual and psychological benefits emerging within 3-6 weeks, metabolic and inflammatory changes within 1-3 months, and structural changes in muscle, bone, and erythropoiesis taking 6-12 months or longer to reach maximum effect.

If you start testosterone therapy, expect improvements in mood, libido, and energy within the first 1-2 months. Do not expect significant changes in muscle mass, fat loss, or bone density until you have been on therapy for 6-12 months. Consistency is key, as structural benefits take much longer to manifest than psychological ones.

Preoperative oral administration of carbohydrate-rich drinks (with or without peptides) reduces postoperative insulin resistance and preserves quadriceps muscle strength compared to traditional overnight fasting.

If you are having major abdominal surgery, ask your medical team if you can drink a specific carbohydrate-rich drink the night before and the morning of your surgery (stopping 3 hours before anesthesia). This is not water; it is a specific medical drink designed to reduce surgical stress and help you keep your muscle strength after the operation. This practice is increasingly common in enhanced recovery protocols.

Dietary proteins regulate gastrointestinal physiology and metabolic functions (including food intake, gastric emptying, and hormone release) through source-specific interactions with the GI tract, distinct from their role as amino acid sources.

When choosing protein sources, recognize that they do more than just build muscle. Different proteins (like casein vs. whey) digest at different rates and trigger different satiety hormones. This means the source of your protein affects your hunger and metabolic response, not just your amino acid intake.

Bioactive peptides (BAPs) derived from dietary proteins can survive digestion, interact with GI receptors, and exert physiological effects such as lowering blood pressure or regulating appetite, even if systemic absorption is limited.

Consuming fermented dairy products or specific protein hydrolysates may provide bioactive peptides that help regulate blood pressure and appetite. These peptides can work by interacting with your gut lining or being absorbed in small amounts, offering benefits beyond basic nutrition.

Different protein sources (e.g., casein vs. whey) have distinct effects on gastric emptying rates and satiety due to their physico-chemical properties and digestion kinetics.

If you want to feel full longer, choose slower-digesting proteins like casein (found in cottage cheese or casein supplements). Faster-digesting proteins like whey will leave your stomach quicker. This difference is due to how they physically behave in the stomach and how they trigger satiety hormones.

Untreated obstructive sleep apnea (OSA) severity is independently associated with worsening glycemic control (higher HbA1c) and insulin resistance in patients with type 2 diabetes, even after adjusting for obesity and other confounders.

If you have type 2 diabetes, your sleep quality matters as much as your diet. Untreated sleep apnea can significantly worsen your blood sugar control (HbA1c) regardless of your weight. Ask your doctor about screening for sleep apnea, especially if you have symptoms like snoring or daytime fatigue, as treating it may help improve your glucose levels.

Oral L-citrulline supplementation (3–10 g/day) effectively increases plasma L-arginine and nitric oxide (NO) bioavailability, leading to reduced resting blood pressure and arterial stiffness in pre-hypertensive and hypertensive populations, whereas it fails to improve endothelial function (FMD) in healthy young individuals.

If you have high blood pressure, taking 3-10 grams of L-citrulline daily (or eating equivalent amounts of watermelon) can help lower your blood pressure and improve artery stiffness. This works best if you are already pre-hypertensive or hypertensive. If you are young and healthy, you likely won't see changes in your blood vessel dilation, so don't expect performance benefits from this specific mechanism.

In women with polycystic ovarian syndrome (PCOS), abdominal obesity significantly worsens insulin resistance, whereas lean PCOS subjects exhibit only a non-significant trend toward impaired sensitivity.

If you have PCOS, your risk for insulin resistance is higher than average, but carrying excess abdominal weight makes it significantly worse. Lean women with PCOS may have mild issues, but obese women with PCOS face substantial metabolic impairment. Prioritizing the reduction of abdominal fat is a critical lever for improving insulin sensitivity in this population.

Black South African women exhibit higher degrees of insulin resistance and elevated free fatty acids compared to white women with similar BMI and body composition, predisposing them to type 2 diabetes despite potentially lower visceral fat.

Healthcare providers should prioritize screening for insulin resistance and diabetes in obese black women, even if their BMI appears moderate, as they are biologically predisposed to these conditions due to higher free fatty acid levels and insulin resistance.

Peripheral administration of PYY3-36 reduces food intake and body weight gain in both lean and obese human subjects by acting on hypothalamic Y2 receptors, with sensitivity preserved in obesity unlike leptin.

Obesity does not necessarily mean you are blind to all satiety signals. Research indicates that the hormone PYY, which signals fullness, still works effectively in obese individuals, unlike leptin. This suggests that therapies targeting the PYY pathway may be effective for weight management in obesity.

GLP-1 receptor agonists (e.g., exenatide, liraglutide) reduce food intake and body weight in humans, but their use is limited by side effects like nausea and potential long-term risks.

GLP-1 agonists are effective for weight loss and diabetes management, but they come with side effects like nausea. Long-term safety data is still being gathered. Consult a doctor to weigh the benefits against the side effects.

Severe sedentary behavior increases the risk of sleep disturbance, and this association is significantly mediated by elevated blood-cell-based inflammatory biomarkers (WBC, NEU, NLR, SII).

If you sit for more than 480 minutes a day (severe sedentary behavior), your risk of sleep disturbance increases. This risk is partly driven by your body's inflammatory response (measurable by blood tests). To mitigate this, you must break up long periods of sitting with movement, as this reduces the inflammatory burden that disrupts sleep.

Marine-derived n-3 polyunsaturated fatty acid (PUFA) supplementation significantly lowers fasting blood levels of C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in subjects with chronic non-autoimmune disease, chronic autoimmune disease, and healthy subjects.

If you are dealing with chronic inflammation, adding marine-derived omega-3 supplements (fish oil) can significantly lower inflammatory markers like CRP and IL-6. This benefit is most pronounced in non-obese individuals (BMI < 30) and those with chronic diseases. For general health, it helps, but for significant inflammation reduction, consistency and duration matter.

Longer duration of marine-derived n-3 PUFAs supplementation leads to a greater lowering effect on IL-6 and TNF-α in subjects with chronic non-autoimmune disease.

To get the most anti-inflammatory benefit from fish oil, you need to take it consistently for a long time. The reduction in inflammatory markers like IL-6 and TNF-α increases the longer you supplement, suggesting a commitment of several months is necessary.

Activation of the PI3K-mTOR signaling pathway by insulin, amino acids, and resistance exercise is the central mechanism regulating skeletal muscle protein synthesis and hypertrophy.

To maximize muscle growth, you must combine resistance exercise with adequate protein intake. The body uses a common signaling pathway (mTOR) to integrate these signals. Simply taking protein supplements or exercising without nutrition is less effective than doing both together, as they synergistically activate the pathway responsible for building muscle.

Treatment with 0.6 mg/day of the long-acting GLP-1 derivative liraglutide for 8 weeks significantly improves glycemic control (reducing fasting glucose and HbA1c) in obese patients with type 2 diabetes without causing weight gain.

If you have type 2 diabetes and are obese, taking 0.6 mg of liraglutide once daily for at least 8 weeks will significantly lower your fasting blood sugar and HbA1c. However, do not expect to lose weight or change your energy expenditure in this timeframe; your weight will likely stay the same. This treatment is effective for blood sugar control without the weight gain often seen with other diabetes drugs.

Liraglutide improves beta-cell function (HOMA-S) in patients with type 2 diabetes, as indicated by a significant increase in HOMA-S compared to placebo.

This treatment helps your pancreas work better at producing insulin in response to blood sugar levels, which is a key factor in managing type 2 diabetes.

Elevated body iron stores, indicated by higher serum ferritin levels, are associated with a significantly increased risk of developing type 2 diabetes.

If you have high ferritin levels, it may indicate an increased risk for type 2 diabetes. This is likely due to oxidative stress damaging insulin-producing cells. You should discuss your ferritin levels with a doctor to determine if phlebotomy or dietary adjustments are appropriate, rather than self-prescribing iron restriction.

In postmenopausal women with a normal body mass index (BMI 18.5–24.9), higher levels of body fat (specifically whole-body and trunk fat) are associated with a significantly elevated risk of invasive breast cancer, particularly estrogen receptor-positive (ER+) subtypes.

If you are a postmenopausal woman with a normal BMI, your body fat percentage still matters for breast cancer risk. High body fat, especially around the trunk, is linked to a significantly higher risk of ER-positive breast cancer, even if your weight is healthy. Focus on maintaining healthy body fat levels through diet and exercise, rather than just focusing on BMI.

Lifestyle modification and metformin treatment can modulate gut microbiota and maintain glucose homeostasis in type 2 diabetes, suggesting similar potential for post-GDM women.

For post-GDM women, lifestyle changes and metformin have been shown to help manage blood sugar and potentially improve gut bacteria. However, adherence to lifestyle changes is often poor after delivery, and metformin's use as a preventive strategy is still debated. Prioritize sustainable lifestyle habits.

Daily Heart Rate Variability (HRV) metrics, when averaged weekly, reveal parasympathetic hyperactivity (increased RMSSD and HF power) in endurance athletes experiencing functional overreaching (F-OR), whereas isolated single-day measurements fail to detect these autonomic changes.

If you are an endurance athlete suspecting overtraining, do not rely on a single daily HRV reading. Instead, record your Heart Rate Variability (specifically RMSSD) every morning upon waking. Calculate the weekly average of these values. A rising trend in your weekly average RMSSD during a heavy training block, accompanied by a drop in performance, is a strong indicator of parasympathetic hyperactivity and functional overreaching, signaling that you need a recovery taper.

Testosterone replacement therapy (TRT) restores serum testosterone to normal ranges, thereby improving mood, energy, sexual function, lean body mass, erythropoiesis, and bone mineral density in hypogonadal men.

If you have clinically low testosterone and symptoms like low energy, low libido, or loss of muscle mass, TRT can restore your levels to normal and improve these symptoms. There are many forms of treatment (gels, patches, injections, buccal tablets) to suit your preference. Regular monitoring of your prostate and blood counts is essential to ensure safety.

Testosterone replacement therapy improves bone mineral density (BMD) and reduces fracture risk in hypogonadal men, with effects mediated by both androgen and estrogen receptors.

If you have low testosterone, you are at higher risk for osteoporosis and fractures. TRT can help build and maintain bone density, bringing it back to normal levels. This is a key benefit beyond just sexual health and muscle mass.

Semaglutide (1.0 mg once-weekly) significantly improves fasting and postprandial glucose and lipid metabolism in subjects with obesity, primarily through delayed first-hour gastric emptying and GLP-1 receptor agonism.

For individuals with obesity, semaglutide (1.0 mg weekly) significantly improves how the body handles glucose and fats after eating. This is achieved by slowing down the initial emptying of the stomach, which prevents rapid spikes in blood sugar and lipids. This benefit occurs even in people without diabetes, suggesting it may be a valuable tool for metabolic health in obesity.